News

However, no safety concerns were raised. As a result of the DSMB findings and recommendation, the company has decided to discontinue the study. Liplong is a randomized, double-blind

The allowed claims relate to human microRNA miR-21, a microRNA that is a potential target for a number of therapeutic indications. Regulus has access to the Tuschl III

Reportedly, the closure is expected to result in the loss of 37 jobs at DSI. DSM has asked the local Works Council for advice on the planned closure.

Patients who had received placebo treatment experienced a 0.22% HbA1c reduction, six months post-treatment. Post prandial and AUC (area under the curve) glucose showed improvement versus placebo but

The study evaluated the efficacy and safety of Orencia in patients six to 17 years of age with moderate to severe active pJIA, who had an inadequate response

Raghav Chari, senior vice president of proprietary products business at Dr Reddy’s, said: “We are extremely pleased to be working with Aegis and gaining access to their patented

Jim Jersey, president and CEO at Agilux, said: “In launching the LC/MS/MS GLP bioanalytical services, we have challenged ourselves to be as innovative as we were in discovery,

The phase III clinical trial was a multi-center, randomised, double-blind, placebo-controlled study. Dose levels of 100 – 1600mcg were tested in the trial. In the double-blind portion of

The Phase 1 trial is an open label, multicenter, dose escalation study of Telintra in combination with lenalidomide in patients with non-deletion (5q-) low to intermediate-1 risk MDS.